Peptide-Based Inhibitors for SARS-CoV-2 and SARS-CoV

Disha Panchal, Jeena Kataria, Kamiya Patel, Kaytlyn Crowe, Varun Pai, Abdul Rahman Azizogli, Neil Kadian, Sreya Sanyal, Abhishek Roy, Joseph Dodd-o, Amanda M. Acevedo-Jake, Vivek A. Kumar

Research output: Contribution to journalReview articlepeer-review

Abstract

The COVID-19 (coronavirus disease) global pandemic, caused by the spread of the SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) virus, currently has limited treatment options which include vaccines, anti-virals, and repurposed therapeutics. With their high specificity, tunability, and biocompatibility, small molecules like peptides are positioned to act as key players in combating SARS-CoV-2, and can be readily modified to match viral mutation rate. A recent expansion of the understanding of the viral structure and entry mechanisms has led to the proliferation of therapeutic viral entry inhibitors. In this comprehensive review, inhibitors of SARS and SARS-CoV-2 are investigated and discussed based on therapeutic design, inhibitory mechanistic approaches, and common targets. Peptide therapeutics are highlighted, which have demonstrated in vitro or in vivo efficacy, discuss advantages of peptide therapeutics, and common strategies in identifying targets for viral inhibition.

Original languageEnglish (US)
Article number2100104
JournalAdvanced Therapeutics
Volume4
Issue number10
DOIs
StatePublished - Oct 2021

All Science Journal Classification (ASJC) codes

  • Medicine (miscellaneous)
  • Pharmacology
  • Pharmaceutical Science
  • Genetics(clinical)
  • Biochemistry, medical
  • Pharmacology (medical)

Keywords

  • coronavirus
  • peptide therapeutics
  • SARS-CoV
  • SARS-CoV-2
  • SARS-CoV-2 mutants

Fingerprint

Dive into the research topics of 'Peptide-Based Inhibitors for SARS-CoV-2 and SARS-CoV'. Together they form a unique fingerprint.

Cite this